Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ Innovative Medicine — Currency translation/Other

Other segment segments

MEDTECH
-$59M-172%

Similar metrics at other companies

Baxter International logo
BAXMedical Products & Therapies — Currency translation and other
$20M+243%
Baxter International logo
BAXPharmaceuticals — Currency translation and other
$9.25M+261%
Ashland logo
ASHLife Sciences — Goodwill Foreign Currency Translation And Other
$4.75M-5.0%
Sysco logo
SYYOther — Currency Translation And Other
$0—
Emerson Electric logo
EMRIntelligent Devices — Foreign currency translation and other
$21.75M-25.0%
Aflac logo
AFLOther — Foreign currency translation and other
$0-100%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:GoodwillOtherIncreaseDecrease.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's innovative medicine — currency translation/other.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's innovative medicine — currency translation/other?
Johnson & Johnson (JNJ) reported innovative medicine — currency translation/other of -$155M in Q1 2026.
How has Johnson & Johnson's innovative medicine — currency translation/other changed year-over-year?
Johnson & Johnson's innovative medicine — currency translation/other decreased by 172.1% year-over-year, from $215M to -$155M.
What is the long-term trend for Johnson & Johnson's innovative medicine — currency translation/other?
Over 2 years (2023 to 2025), Johnson & Johnson's innovative medicine — currency translation/other has grown at a 91.2% compound annual growth rate (CAGR), from $223M to $815M.
What does innovative medicine — currency translation/other mean?
Represents the net impact of foreign currency exchange rate fluctuations and other miscellaneous adjustments on the goodwill balance of the Innovative Medicine segment. This accounts for the revaluation of assets held in non-functional currencies. It helps isolate non-operational changes from organic growth or acquisition-related changes in asset value.